Sign inJoin waitlistJoin the waitlist

Manisha Bhutani

Co-Associate Leader · Wake Forest University Baptist Medical Center

Credentials: · · · · · ·

History

Wake Forest University Baptist Medical Center
Present
Wake Forest University Baptist Medical Center
Present

Clinical Center at the National Institutes of Health
2014–2016
Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2011–2014
Michigan State University College of Human Medicine
2008–2011
Pt. B.D. Sharma PGIMS Rohtak
2004–2008

Research

High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis
Journal of Clinical Oncology · 2011 · 336 citations
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm,…
The Lancet · 2021 · 283 citations
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
JAMA Oncology · 2015 · 267 citations

Saad Usmani
35 papers
Peter Voorhees
30 papers
Shebli Atrash
26 papers · 19 as a resident
Barry Paul
18 papers · 6 as a fellow
NK
Neha Korde
18 papers
Ola Landgren
18 papers
EM
Elisabet Manasanch
16 papers
Mark Roschewski
15 papers
NT
Nishant Tageja
15 papers · 9 as a fellow
MK
Mary Kwok
13 papers · 1 as a fellow
Reed Friend
12 papers · 3 as a fellow
Irina Maric
11 papers

Clinical trials

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Principal investigator · Recruiting
Wake Forest University Health Sciences
2025–2035
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Principal investigator · Active not recruiting · Phase 2
Wake Forest University Health Sciences
2020–2027
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Principal investigator · Completed · Phase 2
Wake Forest University Health Sciences
2018–2025
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Site PI · Recruiting · Phase 1
Caribou Biosciences, Inc.
2023–2027